Hepatitis C Overview

1234567891011121314151617181920212223
Across
  1. 5. NS3/4A protease inhibitor in Mavyret.
  2. 9. Hepatitis C treatment that is the most limited in applications, and is only approved for genotypes 1 and 4.
  3. 10. A major drug interaction exists between this drug and sofosbuvir-based regimens.
  4. 11. NS5A inhibitor in Mavyret.
  5. 14. All direct-acting antivirals are contraindicated with strong ________ inducers.
  6. 17. One major consideration or health factor when choosing hepatitis C treatment.
  7. 19. NS3/4A protease inhibitor unique to Vosevi.
  8. 21. NS5A polymerase inhibitor unique to Harvoni.
  9. 22. The abbreviation used to described undetectable HCV RNA levels 12 weeks after completing treatment
  10. 23. Suffix for NS3/4A protease inhibitors.
Down
  1. 1. NS5A replication complex inhibitor in Zepatier.
  2. 2. NS3/4A protease inhibitor in Zepatier.
  3. 3. The leading cause of liver transplants and liver cancer.
  4. 4. Patients taking direct-acting antivirals should be tested and monitored for HBV infection due to risk of __________.
  5. 6. NS5B polymerase inhibitor contained in Epclusa, Harvoni, and Vosevi.
  6. 7. Acronym for the first-line treatment for hepatitis C.
  7. 8. Hepatitis C treatment that is approved for genotypes 1, 4, 5, and 6.
  8. 12. Suffix for NS5B polymerase inhibitors.
  9. 13. Suffix for NS5A replication complex inhibitors.
  10. 15. A one tablet once daily hepatitis C treatment option that must be taken with food.
  11. 16. Hepatitis C treatment that must be taken as 3 tablets once daily.
  12. 18. Treatment that can be combined with direct-acting antivirals for patients who failed prior treatment.
  13. 20. Hepatitis C treatment that cannot be taken with proton pump inhibitors.